Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPD-DARA Study in Relapsed/Refractory Multiple Myeloma
NCT04667663Phase 1Active, not recruiting
- Sponsor
- Cancer Trials Ireland
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by Cancer Trials Ireland. Primary endpoint: Dose Limiting Toxicity. Started Dec 2021; status: active, not recruiting.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04667663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667663.